Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04724590
Other study ID # 83045809-604.01.02
Secondary ID 159075
Status Recruiting
Phase N/A
First received
Last updated
Start date December 3, 2020
Est. completion date May 3, 2021

Study information

Verified date January 2021
Source Istanbul University-Cerrahpasa
Contact Meltem Dagdelen, MD
Phone +905426603810
Email meltemdagdelen@windowslive.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary treatment in nasopharynx cancers is radiotherapy (RT) or chemoradiotherapy (CRT) depending on the stage of the tumor. According to the guidelines, the dose of radiotherapy for primary tumors varies between 66-70 Gy. In consideration of modern radiotherapy techniques like IMRT with systemic chemotherapy for nasopharyngeal cancer, loco-regional control has been perfect. However, the rate of late complications from treatment, many of which are irreversible, is still high. Radiation-related optic neuropathy is the late complication that optic nerves might be affected during the radiotherapy due to the close location of the nasopharynx. Incidence of this is 8.7-9% in head and neck cancer and is observed between 2-9 years after RT. Painless, irreversible, and progressive vision loss usually occurs, and the pallor of optic disc margins, retinal vein dilatation, bleeding, and neovascularization are in the ophthalmic examination. The risk of optic neuropathy increases when the tumor is in close contact with optic nerves, radiation dose, concurrent chemotherapy used, history of diabetes or hypertension. The aim of our study is to prospectively evaluate optic neuropathy in nasopharynx cancer patients treated in our clinic.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date May 3, 2021
Est. primary completion date April 3, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patient with nasopharyngeal carcinoma that histopathologically confirmed Age >18 Radiotherapy or chemoradiotherapy applied to the patient in our clinic No recurrence or metastasis during follow-up Optic evaluation Evaluation with MRI or CT during follow-up Exclusion Criteria: Cranial RT No histopathological verification Age< 18 There were locoregional recurrence or metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )
Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.

Locations

Country Name City State
Turkey Meltem Dagdelen Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University-Cerrahpasa

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCINOMA (ORONIN) RADIATION-RELATED OPTIC NEUROPATHY RADIATION-RELATED OPTIC NEUROPATHY 2-9 years